Publisher's Synopsis
Since their development 30 years ago Beta-adrenoceptor antagonists have been proved to be among the most efficacious forms of drug treatment both for ischaemic heart disease and high blood pressure. In order to improve their efficacy and to reduce inherent disadvantages, a number of third-generation compounds have been developed, of which carvedilol is one. However, comprehensive knowledge of their long-term pharmacodynamic and therapeutic efficacy is still being accumulated. This publication presents the proceedings of an international symposium, attended by recognised authorities in the field, which was organised to review the present state of pharmacotherapeutic knowledge on carvedilol in the treatment of high blood pressure, ischaemic heart disease, cardiac arrhythmias and heart failure. The data presented and discussed at the meeting are of vital interest to all those concerned with the treatment of cardiac patients.
